Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 135.85% | 175.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 135.85% | 175.90% | |||
| Cost of Revenue | -6.58% | -- | |||
| Gross Profit | 165.48% | -347.30% | |||
| SG&A Expenses | -6.26% | -16.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.48% | 33.78% | |||
| Operating Income | 86.57% | -3.72% | |||
| Income Before Tax | -2.80% | -19.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.80% | -19.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.80% | -19.44% | |||
| EBIT | 86.57% | -3.72% | |||
| EBITDA | 88.64% | -4.73% | |||
| EPS Basic | 63.04% | -72.13% | |||
| Normalized Basic EPS | 63.06% | -72.16% | |||
| EPS Diluted | 63.04% | -72.13% | |||
| Normalized Diluted EPS | 63.06% | -72.16% | |||
| Average Basic Shares Outstanding | 178.05% | -30.62% | |||
| Average Diluted Shares Outstanding | 178.05% | -30.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||